Cardiovascular · 510(k) · 2019

Zio XT ECG Monitoring System, Zio AT ECG Monitoring System

iRhythm Technologies, Inc.. Cleared by FDA on 23 August 2019 under submission K190593, product code DQK (computer, diagnostic, programmable). What FDA's record says, in FDA's words.

Device record · K190593

  1. Device. Zio XT ECG Monitoring System, Zio AT ECG Monitoring SystemDEVICE
  2. Company. iRhythm Technologies, Inc.COMPANY
  3. Decision. 23 August 2019, 510(k), substantially equivalent (traditional review); received 7 March 2019DECISION
  4. Panel. CardiovascularPANEL
  5. Product code. DQK, Computer, Diagnostic, ProgrammableCODE
  6. Regulation. 21 CFR 870.1425, Class IIREG
  7. Source. FDA database entry · decision document (7 pages)SOURCE

Retrieved · the fields above are FDA's; the statement below was copied from the decision document on that day.

What FDA cleared it for

The Indications for Use statement, verbatim, from the decision document.

The Zio ECG Utilization Service (ZEUS) System is intended to analyze and report symptomatic and asymptomatic cardiac events and continuous electrocardiogram information for long-term monitoring. After patient monitoring by Zio XT or Zio AT Patch, a final report is generated based on the beat-to-beat information from the entire ECG recording. It is indicated for use on patients 18 years or older who may be asymptomatic or who may suffer from transient symptoms such as palpitations, shortness of breath, dizziness, light-headedness, pre-syncope, syncope, fatigue, or anxiety and patients who are asymptomatic. The reports are provided for review by the intended user to render a diagnosis based on

K190593, FDA decision document · source

What the statement says

Pattern matches on the Indications for Use text. Each line is a fact that the text contains the words, not a finding about the device.

Adverse-event reports in MAUDE, by product code

As of , MAUDE held 4,558 reports filed against devices carrying product code DQK. That code is shared by every device of this type, not this device alone, and MAUDE reports are submitted by manufacturers, facilities and the public without FDA verification. The latest reports, in the reporter’s words:

30 September 2026 · Malfunction · QUANTIEN · Abbott Medical · report 2184149-2026-00257

During a fractional flow reserve procedure with QUANTIEN, it was noted that the PA signals were not appearing on the monitor leading to the procedure being cancelled. There were no adverse patient consequences.

29 September 2026 · Malfunction · Smart Pressure Controller · Edwards LifeSciences · report 2015691-2026-18928

29 September 2026 · Malfunction · Smart Pressure Controller · Edwards LifeSciences · report 2015691-2026-18932

29 September 2026 · Malfunction · Smart Pressure Controller · Edwards LifeSciences · report 2015691-2026-18933

29 September 2026 · Malfunction · Smart Pressure Controller · Edwards LifeSciences · report 2015691-2026-18934

Where this fits

This page is a record, not medical advice and not a safety rating. It copies FDA's fields and FDA's statement, and lists what the statement's text mentions. Read the labeling before relying on any of it.

More devices under product code DQK, in Cardiovascular, from iRhythm Technologies, Inc., or cleared in 2019. The whole record is at FDA AI-enabled medical devices.

A device's authorized use is a sentence the record can be read against. What Apodicta does on a medical record is that reading: every line of a note, a claim or a report proved to its source or held, before it renders.

Show me on one of my files →

This device is authorized for a stated use. See a record read against what it must prove, on your own file.

Show me on my files